An enzyme having a NMDA antagonist activity and/or an anticholinergic activity, wherein the enzyme is selected from the group including phosphotriesterases and phosphotriesterases derivatives. A method for treating a disease, disorder or condition of the central nervous system in a subject, wherein the method includes administering to the subject the enzyme is also described.
